Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study

Blood (2016) 128 (22): 5476.

https://doi.org/10.1182/blood.V128.22.5476.5476

Published: 2016

Journal Articles

Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study

Damianos Sotiropoulos, Vassilios Papadopoulos, Maria Dimou, Despoina Kyriakou, George Papaioannou, George Karavalakis, Emmanuel Papadakis, Maria Palasopoulou, Anastasia Banti, Taxiarchis Kourelis, Alexandra Kouraklis, Theodoros Marinakis, Nora-Athina Viniou, Eleftheria Hatzimichael, Diamantina Vasilatou, George Vassilopoulos, MDPhD, Panayiotis Panayiotidis, Achilles Anagnostopoulos

Blood (2015) 126 (23): 5192.

https://doi.org/10.1182/blood.V126.23.5192.5192

Published: 2015

Journal Articles

Utility of CD81 Flow Cytometry (FC) Assessment In Diagnostic Evaluation of Plasma Cell (PC) Disorders

Haris Kartsios, MD, Vassilios Papadopoulos, Smaragda Effraimidou, Kyriaki Kokoviadou, Anastasia Spyrou, Eleni Gatsa, Anna Kioumi, Ioannis Korantzis

Blood (2010) 116 (21): 3011.

https://doi.org/10.1182/blood.V116.21.3011.3011

Published: 2010

Journal Articles

The Combination of Azacitidine (AZA) and Recombinant Erythropoietin (rEPO) Can Induce Rapidly Hematological Response In Intermediate-2 and High-risk MDS (including RAEB-t)

Haris Kartsios, MD, Kostas Loukidis, MD, Vassilios Papadopoulos, Smaragda Effraimidou, Anastasia Spyrou, Kyriaki Kokoviadou, Emmanouil Papadakis, Anna Kioumi, Ioannis Korantzis

Blood (2010) 116 (21): 2914.

https://doi.org/10.1182/blood.V116.21.2914.2914

Published: 2010

Journal Articles

Dynamics of Telomere Length and Telomerase Activity in Ph 1 -Negative Chronic Myeloproliferative Disorders

Ioanna Bazdiara, Despina Pantelidou, Athanasios Anastasiadis, Vassilios Papadopoulos, Dimitrios Margaritis, Emmanouil Spanoudakis, Georgios Xanthopoulidis, Ioannis Kotsianidis, Anna Christoforidou, Aggelos Goutzouvelidis, Georgios Bourikas, Konstantinos Tsatalas

Blood (2008) 112 (11): 2789.

https://doi.org/10.1182/blood.V112.11.2789.2789

Published: 2008

NARROW

Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study

Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study

Utility of CD81 Flow Cytometry (FC) Assessment In Diagnostic Evaluation of Plasma Cell (PC) Disorders

The Combination of Azacitidine (AZA) and Recombinant Erythropoietin (rEPO) Can Induce Rapidly Hematological Response In Intermediate-2 and High-risk MDS (including RAEB-t)

Dynamics of Telomere Length and Telomerase Activity in Ph 1 -Negative Chronic Myeloproliferative Disorders

Email alerts

ASH Publications

American Society of Hematology

Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study

Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study

Utility of CD81 Flow Cytometry (FC) Assessment In Diagnostic Evaluation of Plasma Cell (PC) Disorders

The Combination of Azacitidine (AZA) and Recombinant Erythropoietin (rEPO) Can Induce Rapidly Hematological Response In Intermediate-2 and High-risk MDS (including RAEB-t)

Dynamics of Telomere Length and Telomerase Activity in Ph 1 -Negative Chronic Myeloproliferative Disorders

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only